MX386900B - Compuestos para formacion de imagenes de agregados de proteinas tau. - Google Patents

Compuestos para formacion de imagenes de agregados de proteinas tau.

Info

Publication number
MX386900B
MX386900B MX2018016279A MX2018016279A MX386900B MX 386900 B MX386900 B MX 386900B MX 2018016279 A MX2018016279 A MX 2018016279A MX 2018016279 A MX2018016279 A MX 2018016279A MX 386900 B MX386900 B MX 386900B
Authority
MX
Mexico
Prior art keywords
compounds
tau protein
protein aggregates
imaging tau
imaging
Prior art date
Application number
MX2018016279A
Other languages
English (en)
Other versions
MX2018016279A (es
Inventor
Andre Müller
Emanuele Gabellieri
Felix Oden
Hanno Schieferstein
Heiko Kroth
Heribert Schmitt-Willich
Jérôme Molette
Mathias Berndt
Vincent Darmency
Original Assignee
Ac Immune S A Star
Life Molecular Imaging Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ac Immune S A Star, Life Molecular Imaging Ltd filed Critical Ac Immune S A Star
Publication of MX2018016279A publication Critical patent/MX2018016279A/es
Publication of MX386900B publication Critical patent/MX386900B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)

Abstract

La presente invención se refiere a compuestos novedosos de la fórmula (II) que pueden emplearse en la detección selectiva de Tau de trastornos y anomalías asociadas con agregados de Tau, como la enfermedad de Alzheimer y otras tauopatías, usando la formación de imágenes de tomografía por emisión de positrones (PET).
MX2018016279A 2016-07-22 2017-07-21 Compuestos para formacion de imagenes de agregados de proteinas tau. MX386900B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16180908 2016-07-22
PCT/EP2017/068509 WO2018015549A1 (en) 2016-07-22 2017-07-21 Compounds for imaging tau protein aggregates

Publications (2)

Publication Number Publication Date
MX2018016279A MX2018016279A (es) 2019-09-06
MX386900B true MX386900B (es) 2025-03-19

Family

ID=56550098

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018016279A MX386900B (es) 2016-07-22 2017-07-21 Compuestos para formacion de imagenes de agregados de proteinas tau.

Country Status (13)

Country Link
US (1) US10835624B2 (es)
EP (1) EP3487544A1 (es)
JP (1) JP7197476B2 (es)
KR (1) KR102472003B1 (es)
CN (2) CN109475648B (es)
AU (1) AU2017299219B2 (es)
BR (1) BR112019000946A8 (es)
CA (1) CA3030511C (es)
IL (2) IL264239B (es)
MX (1) MX386900B (es)
MY (1) MY196981A (es)
SG (1) SG11201811311VA (es)
WO (1) WO2018015549A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7059270B2 (ja) * 2016-07-22 2022-04-25 エーシー・イミューン・エス・アー タウタンパク質凝集体を画像化するための化合物
US11306089B2 (en) * 2018-01-24 2022-04-19 Life Molecular Imaging Limited Gamma-carboline compounds for the detection of Tau aggregates
CN111868062B (zh) * 2018-01-24 2023-07-07 Ac免疫有限公司 制备显像化合物的方法
CA3088232A1 (en) * 2018-01-24 2019-08-01 Ac Immune Sa Diagnostic compositions for pet imaging, a method for manufacturing the diagnostic composition and its use in diagnostics
JP7702381B2 (ja) * 2019-07-08 2025-07-03 アルゼカ バイオサイエンシズ、エルエルシー タウ病理のためのターゲティングリガンド
KR102594570B1 (ko) * 2020-11-12 2023-10-26 사회복지법인 삼성생명공익재단 질소를 함유하는 헤테로아렌 화합물 기반 방사성 리간드 및/또는 비방사성 리간드의 합성 방법

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932557B2 (en) 2008-02-14 2015-01-13 Eli Lilly And Company Imaging agents for detecting neurological dysfunction
WO2009102498A1 (en) 2008-02-14 2009-08-20 Siemens Medical Solutions Usa, Inc. Novel imaging agents for detecting neurological dysfunction
US8691187B2 (en) 2009-03-23 2014-04-08 Eli Lilly And Company Imaging agents for detecting neurological disorders
MX2013005545A (es) 2010-11-16 2013-08-01 Ge Healthcare Ltd Compuestos heterociclicos como sodas de imagenologia de la patologia tau.
US20130230460A1 (en) 2010-11-19 2013-09-05 Ge Healthcare Limited Use of cyanine dyes for the detection of tau for diagnosis of early-stage tauopathies
CA2873963C (en) 2012-05-22 2017-04-11 Eli Lilly And Company Carboline and carbazole based imaging agents for detecting neurological dysfunction
KR20150042787A (ko) 2012-08-14 2015-04-21 에프. 호프만-라 로슈 아게 알츠하이머병의 진단 시약으로서 유용한 이미다조[2,1]티아졸-3-온 유도체
RU2015147450A (ru) 2013-04-29 2017-06-05 Ф. Хоффманн-Ля Рош Аг ПРОИЗВОДНЫЕ 2-ФЕНИЛ ИЛИ 2-ГЕТЕРОАРИЛ ИМИДАЗОЛ[1,2-a]ПИРИДИНА
ES2629389T3 (es) 2013-05-23 2017-08-09 H. Hoffnabb-La Roche Ag 2-fenilimidazo[1,2-a]pirimidinas como agentes de obtención de imágenes
US20160115162A1 (en) 2013-05-31 2016-04-28 The General Hospital Corporation Radiosynthesis of Tau Radiopharmaceuticals
JP6182668B2 (ja) 2013-09-26 2017-08-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 画像化ツールとしてのイミダゾ［１，２−ａ］ピリジン−７−アミン
PT3055308T (pt) * 2013-10-08 2018-01-18 Hoffmann La Roche Resumo
US10662193B2 (en) * 2014-01-21 2020-05-26 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins
MX384604B (es) 2014-05-13 2025-03-14 Hoffmann La Roche Compuestos heterocíclicos deuterados y su uso como agentes formadores de imágenes.
WO2015188368A1 (en) 2014-06-13 2015-12-17 Merck Sharp & Dohme Corp. Pyrrolo[2,3-c]pyridines as imaging agents for neurofibrilary tangles
US9744251B2 (en) 2014-10-08 2017-08-29 Texas Children's Hospital MRI imaging of amyloid plaque using liposomes
WO2016124508A1 (en) * 2015-02-02 2016-08-11 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
KR20170126965A (ko) 2015-03-02 2017-11-20 고쿠리쓰 겐큐 가이하쓰 호징 리가가쿠 겐큐소 고분자 화합물 및 고분자 화합물의 제조 방법

Also Published As

Publication number Publication date
IL295000B2 (en) 2023-08-01
US20190262480A1 (en) 2019-08-29
CA3030511A1 (en) 2018-01-25
JP2019523298A (ja) 2019-08-22
RU2019104415A (ru) 2020-08-24
KR102472003B1 (ko) 2022-11-29
CA3030511C (en) 2024-06-18
MX2018016279A (es) 2019-09-06
BR112019000946A8 (pt) 2022-12-13
CN115650982A (zh) 2023-01-31
AU2017299219B2 (en) 2022-12-22
CN109475648B (zh) 2023-03-14
IL295000B1 (en) 2023-04-01
AU2017299219A1 (en) 2019-01-17
EP3487544A1 (en) 2019-05-29
BR112019000946A2 (pt) 2019-04-30
KR20190031312A (ko) 2019-03-25
IL264239B (en) 2022-08-01
IL264239A (en) 2019-02-28
IL295000A (en) 2022-09-01
CN109475648A (zh) 2019-03-15
SG11201811311VA (en) 2019-01-30
US10835624B2 (en) 2020-11-17
JP7197476B2 (ja) 2022-12-27
RU2019104415A3 (es) 2020-11-26
MY196981A (en) 2023-05-16
WO2018015549A1 (en) 2018-01-25

Similar Documents

Publication Publication Date Title
MX386900B (es) Compuestos para formacion de imagenes de agregados de proteinas tau.
EA201791167A1 (ru) Способы и композиции для мечения радиоактивным изотопомf биологических препаратов
CY1122265T1 (el) Αντισωματα εναντι ταυ και χρησεις αυτων
EA201791733A1 (ru) Производные 9h-пирролодипиридина
MX2019007480A (es) Anticuerpos monoclonales anti-alfa-sinucleina para prevenir la agregacion de tau.
EA201890747A1 (ru) Способы лечения воспалительных заболеваний
PH12017500032B1 (en) Improved a㟠protofibril binding antibodies
BR112019009172A2 (pt) formulações para radioterapia e diagnóstico por imagem.
EA201691529A1 (ru) Гетероарильные амиды в качестве ингибиторов агрегации белков
MX2019003805A (es) Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías.
UY36178A (es) Novedosos derivados de ácido heteroaril-butanoico
WO2014160871A3 (en) Methods and agents for treating alzheimer's disease
CY1124115T1 (el) Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες
EA201890815A1 (ru) Аминокислотные композиции с модифицированным высвобождением для перорального введения
AR107786A1 (es) Métodos y composiciones para la detección y el diagnóstico de enfermedad renal y enfermedad periodontal
EP3283128A4 (en) TRANSMETALIZATION PROCEDURE FOR SYNTHESIS OF PET AND SPECT CONTRASTANTS
JO3565B1 (ar) الأجسام المضادة لشبيه الأنجيوبوييتين– 4 وطرق استخدامها
ZA201804079B (en) Lactoferrin for use in the diagnosis or prognosis of alzheimer's disease, or in the diagnosis of parkinson's disease
MX2018000528A (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
CO2020008834A2 (es) Nuevo método para preparar compuesto para formación de imágenes
SI3413870T1 (sl) Igmezin za uporabo pri zdravljenju alzheimerjeve bolezni
EP3475442C0 (en) 12(S)-HYDROXYEICOSATRIENOIC ACID COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS
MX2017009452A (es) Agentes de imagenologia para tomografia de emision de positrones (pet).
MX375468B (es) Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis.
RU2014138694A (ru) Состав для стимуляции метаболических процессов, системы иммунитета, профилактики заболеваний диареей